Orchestra BioMed Holdings, Inc.OBIO财报
Nasdaq · 医疗保健 · 外科及医疗仪器和设备
Orchestra BioMed Holdings是一家临床阶段医疗科技企业，专注于开发针对心血管及其他高负担慢性疾病的新型循证治疗方案，核心业务覆盖介入心脏病学、慢病护理优化等领域，主要面向北美、欧洲市场运营，与头部医疗行业参与者开展合作。
主要股东
| 股东 | 持股比例 | 股数 | 变动 | 截至 |
|---|---|---|---|---|
| RTW Investments, LP | 21.50% | 7.7M | — | 2024-08-07 |
| Medtronic plc | 16.40% | 5.9M | — | 2024-02-14 |
| RTW | 15.70% | 5.6M | — | 2023-05-05 |
| Perceptive Advisors LLC | 12.80% | 4.6M | ▲ +6.00pp | 2024-07-17 |
| BlackRock, Inc. | 5.10% | 1.9M | 无变化 | 2024-11-08 |
| HSAC | 4.80% | 1.7M | — | 2024-08-07 |
| T. ROWE PRICE ASSOCIATES, INC. | 1.70% | 622.6K | — | 2024-02-14 |
内部人交易
Net 90d: +$42.9K · buys $42.9K / sells $0时间范围:
类型:
身份:
| 内部人 | 身份 | 类型 | ||||
|---|---|---|---|---|---|---|
| 2026-03-13 | Hochman David P | See Remarks | Buy (open market) | 10.0K | $4.29 | $42.9K |
| 2026-02-12 | Darren Sherman | See Remarks | Grant | 397.0K | $0.00 | $0 |
| 2026-02-12 | Taylor Andrew Lawrence | Chief Financial Officer | Grant | 181.0K | $0.00 | $0 |
| 2026-02-12 | Hochman David P | See Remarks | Grant | 504.0K | $0.00 | $0 |
1–4 of 4